Präsentation Uppaluri et al.; Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: Phase 3 KEYNOTE-689 Stuy; ACCR 2025